Incyte Corp (INCY)
$81.21 3.09 (3.96%)
17:01 EDT INCY Stock Quote Delayed 15 Minutes
Previous Close $81.21
Market Cap 17.21B
PE Ratio -106.86
Volume (Avg. Vol.) 2.21M
Day's Range 78.37 - 81.64
52-Week Range 57.00 - 89.30
Dividend & Yield N/A (N/A)
INCY Stock Predictions, Articles, and Incyte Corp News
- From InvestorPlace
- From the Web
Activision Blizzard, Incyte and Darden are just some of the stocks to buy for investors looking for gains in September.
With August now upon us, not only is the overbought market vulnerable to profit-taking, the calendar is working against stocks as well. One average, the market loses ground rather than gains ground in the month of August, as well as for September.
Biotech stocks have been looking rough lately, and these four names have been helping to lead the charge lower.
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
PayPal, Slack, and chip stocks like AMD and Nvidia, Micron and Nio were all big movers in the Nasdaq today. Get the scoop, now.
Despite the trade dispute with China, these biotech stocks each earn top marks in Portfolio Grader for fundamentals, earnings and momentum.
The stock charts of INCY, LYB and FMC are going to start this week's hump-day at a precipice. Here are the numbers to know.
The stock charts of COG, INCY and SRE are worth a closer technical look at the midpoint of the trading week.
The stock charts of PFE, INCY and MGM are finally making good on previously-suggested promise.
The stock charts of INCY, ABT and SLB are set to end the week on a more definitive, trade-worthy footing than most other names.
The stock charts of SLG, INCY and ETR are shaping up as the best trading bets as the new week kicks off.
Incyte (INCY) was falling hard on Friday following news of a failed Phase 3 drug trial for its melanoma drug epacadostat.
If you’re itching to buy, avoid these stocks at all costs. Here's what makes them stocks to sell for all wise investors.
Biotech stocks had a great run in 2017. The new year could have more big gains ahead. Here are 5 top biotech stocks to buy today.
Incyte Corp (NASDAQ:INCY) is a $22.2 billion in market value member of the Biotechnology GICS industry group where Portfolio Grader's current ranking for INCY puts it 171 among the 349 companies in this industry group, placing it in the top half. INCY is ranked in the third quartile of the sector with a ranking of 402 among the 785 companies in the sector and number 2,601 in the 5000 company Portfolio Grader company universe.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Eagle Materials Inc (EXP), where a total of 1,985 contracts have traded so far, representing approximately 198,500 underlying shares. That amounts to about 43.6% of EXP's average daily trading volume over the past month of 455,540 shares..
Investors in Incyte Corporation (INCY) saw new options become available this week, for the January 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 857 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!